TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/14/2025
Back to search
Official data from USPTO
BTG
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
75
Latest update
02/18/2025
Classification
Registered
Trademark type
Combined
Nice classes
1, 5, 10, 42
Filing date
10/27/2009
Registration date
10/12/2010
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/24/2021
Last transaction
02/18/2025
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
Filing basis
Intent to use
Drawing code
3
Owner type
24
Owner location
London, GB
Examiner
FRYE,KIMBERLY
Law office
M40
Current location
TMO LAW OFFICE 113
Mark description
The mark consists of a circle with four lines inside of it; below the circle are the letters "BTG" in stylized lettering.
Holders and representatives
Holders
PROTHERICS MEDICINES DEVELOPMENT LIMITED
BTG International Limited
Representatives
Jonathan A. Hyman Knobbe, Martens, Olson & Bear, LLP
Technical classification
Nice Classes
Class 1Class 5Class 10Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals used in science; chemicals for clinical research use; diagnostic reagents and substances for clinical and medical laboratory use; diagnostic reagents and substances for clinical and medical laboratory in vitro research use; polyclonal antibodies and fragments thereof for clinical research use; diagnostic reagents and substances for in vivo clinical and laboratory research use; chemical reagents for scientific research use; chemicals used in science and medicineadjuvant compositions for use in the manufacture of vaccines and antibodies and antibody fragments for use in diagnostics and assays; cell lines for use in production of whole cell derived vaccines; cell lines for use in research related to virus mediated disease
Class 5
Pharmaceutical and medicinal preparations and substances namelyvaccines and vaccine adjuvantsproteinspeptidessera containing polyclonal antibodies and fragments thereof and polyclonal antibodies and fragments derived therefrom all for use in treating snake envenomationoverdose of toxic substances or sepsis; pharmaceutical preparations and substances for the treatment of thrombosisinflammationautoimmune disease and sleep disorders; dietetic foods adapted for medical use; vaccines; sera; polyclonal antibodies and fragments thereof for in vitro disease testing and for use in treating snake envenomationoverdose of toxic substances or sepsis; pharmaceutical preparations in the form of foams or for use in producing foams for use in sclerotherapyphlebologyangiology and proctologyfor treatment of oesophageal variceshydrocelesin sterilisation treatment or for treatment of varicose veins or arteriovenous malformations; chemical reagents for medical or veterinary purposes; chemical reagents for therapeutic and diagnostic purposesfor the treatment of and the diagnosis of the presence of toxic substances; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the reduction or elimination of circulating cytokines; pharmaceutical preparations for the treatment of neurodegeneration and multiple sclerosis; pharmaceutical preparations for the treatment of painincluding headache and migraine; pharmaceutical preparations for promoting the healing of dermal wounds and chronic wounds including ulcers and pressure sores; pharmaceutical and veterinary preparations for the treatment of digoxindigitalis or other cardio-active glycoside toxicity; pharmaceutical preparations for the treatment of envenomation with snake venom; pharmaceutical preparations for treatment of excess levels of cancer agents; pharmaceutical preparations for the treatment of toxic levels of other pharmaceutical agents; pharmaceutical preparations for the treatment of cytotoxic cancer treatment drug overdoseparticularly overdose with methotrexate; pharmaceutical preparations for the treatment of sleep apnea; pharmaceutical preparations for the treatment of head lice; diagnostic reagents for medical use and for the determination of levels of toxic substances in blood and tissue samples in vitro
Class 10
Surgical apparatus for the treatment of varicose veins; medical syringes; cannula needlesmedical tubing for administering drugs; surgical and medical apparatus for producing and administering pharmaceutical foams; surgical or medical apparatus for producing foams for treatment of varicose veinsarterio-venous malformationsoesophageal varices or hydroceles; devices for intravenous administration of pharmaceutical foam; diagnostic devices for grading the severity of venous conditionssnake envenomation and toxic drugs overdose
Class 42
Product research and developmentdevelopment of pharmaceuticals and medical devices through preclinical and clinical research in the fields of envenomationdrug overdosechemical poisoningvenous diseaseautoimmune diseasepain and inflammation and cancer therapy
Publications
History of USPTO decisions and trademark events.
75 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/14/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/14/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/14/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/14/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/13/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/13/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/13/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/16/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/16/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/16/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/16/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/16/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/12/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/12/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
04/12/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/12/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/12/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/12/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
08/30/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/30/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/30/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/30/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
08/30/2021
NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
06/24/2021
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
06/24/2021
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
06/24/2021
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
06/22/2021
PR89
POST REGISTRATION ACTION MAILED - SEC. 8 & 9
06/09/2021
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
04/14/2021
E89R
TEAS SECTION 8 & 9 RECEIVED
04/09/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
08/29/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/29/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/29/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/29/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
08/29/2020
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
10/12/2019
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
04/21/2017
8.PR
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED
04/21/2017
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
04/21/2017
ES8R
TEAS SECTION 8 RECEIVED
04/05/2017
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/05/2017
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
10/12/2015
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/15/2014
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/15/2014
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/14/2011
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/06/2011
R.PR
REGISTERED-PRINCIPAL REGISTER
10/12/2010
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/27/2010
PUBO
PUBLISHED FOR OPPOSITION
07/27/2010
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
06/22/2010
ALIE
ASSIGNED TO LIE
06/21/2010
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/04/2010
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/28/2010
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/28/2010
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/28/2010
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
05/26/2010
GPRA
PRIORITY ACTION E-MAILED
05/26/2010
CPRA
PRIORITY ACTION WRITTEN
05/26/2010
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/07/2010
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/07/2010
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
05/07/2010
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
04/21/2010
GNSL
LETTER OF SUSPENSION E-MAILED
04/21/2010
CNSL
SUSPENSION LETTER WRITTEN
04/21/2010
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/31/2010
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/31/2010
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/31/2010
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/01/2010
GNRT
NON-FINAL ACTION E-MAILED
02/01/2010
CNRT
NON-FINAL ACTION WRITTEN
02/01/2010
DOCK
ASSIGNED TO EXAMINER
02/01/2010
MDSC
NOTICE OF DESIGN SEARCH CODE MAILED
10/31/2009
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/30/2009
NWAP
NEW APPLICATION ENTERED
10/30/2009
Continuous trademark protection
Get notified about every new filing that threatens BTG or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.